Zobrazeno 1 - 10
of 1 916
pro vyhledávání: '"S. DeStefano"'
Autor:
Jackson, Jerome A.
Publikováno v:
The Wilson Bulletin, 1998 Sep 01. 110(3), 453-454.
Externí odkaz:
https://www.jstor.org/stable/4163987
Autor:
Palmer, William S.
Publikováno v:
The Reading Teacher, 1974 Nov 01. 28(2), 208-210.
Externí odkaz:
https://www.jstor.org/stable/20193712
Autor:
Dahl, Sandra S.
Publikováno v:
The Reading Teacher, 1979 Feb 01. 32(5), 613-615.
Externí odkaz:
https://www.jstor.org/stable/20194832
Autor:
Beason, Robert C.
Publikováno v:
Journal of Field Ornithology, 1997 Jul 01. 68(3), 500-500.
Externí odkaz:
https://www.jstor.org/stable/4514252
Autor:
Rystrom, Richard
Publikováno v:
Journal of Reading, 1973 Oct 01. 17(1), 71-73.
Externí odkaz:
https://www.jstor.org/stable/40031317
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. These studies evaluated oral doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f111618736da9ee289e830a7ce3c197e
https://doi.org/10.1093/ofid/ofac492.1334
https://doi.org/10.1093/ofid/ofac492.1334
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing, oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria (NTM). The standard of care therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc7dc27598503a5f3eb43b20ddd042fc
https://doi.org/10.1093/ofid/ofac492.1342
https://doi.org/10.1093/ofid/ofac492.1342
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing, oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. We evaluated the effects of selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc4523917a2a3b99d6f30925999bdd5b
https://doi.org/10.1093/ofid/ofac492.1343
https://doi.org/10.1093/ofid/ofac492.1343
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in t
Externí odkaz:
https://doaj.org/article/69d6484fc7294b1193160ca1e71e7868
Autor:
A C Jirmo, R Grychtol, S Gaedcke, B Liu, S Destefano, C Happle, O Halle, J T Monteiro, O D Breiholz, D Deluca, G Hansen
Publikováno v:
03.02 - Airway cell biology and immunopathology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6244d4612e22d954402743ceaea7b59e
https://doi.org/10.1183/13993003.congress-2022.2999
https://doi.org/10.1183/13993003.congress-2022.2999